Breast cancer is the most commonly diagnosed cancer among women worldwide, with estrogen receptor-positive (ER+) subtypes accounting for the majority of cases. Resistance to standard endocrine therapies, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors, remains a significant clinical challenge. Selective Estrogen Receptor Degraders (SERDs) have emerged...